Conditions: Portal Hypertension
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 9
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at two dose levels) as compared to placebo for lowering portal hypertension.

Detailed description:

Arms:
arm 1: Participants receive matching placebo capsules three times daily (TID) arm 2: Participants receive 12 mcg Cobiprostone TID arm 3: Participants receive 18 mcg Cobiprostone TID

Interventions: intervention 1: Placebo intervention 2: Cobiprostone
Intervention descriptions: intervention 1: Matching placebo capsules for oral administration intervention 2: Cobiprostone capsules for oral administration

Protocol document: